Endocrine Abstracts

Aim of the study: The objectives of this study were to determine the regulation of glycemia (measured by fasting glucose levels and HbA1c) in patients with type 2 diabetes and to examine whether there is a difference in therapy (oral antidiabetics, insulin, combination), age, sex and BMI.

Study design: Cross-sectional research with historical data.

Patients: The study included 102 patients of both sexes (56% women and 44% men) with a diagnosis of type 2 diabetes who were examined in the Health Center Osijek, Croatia.

Materials and Methods: The following data were collected in family medicine clinics: age, sex, body weight and height, as well as data from laboratory findings (fasting glucose levels, HbA1c, AST, ALT, urea, creatinine, total cholesterol, HDL-cholesterol, LDL- cholesterol, triglycerides).

Results: HbA1c and median glucose levels were lowest in subjects on oral antidiabetic therapy (6.9% and 7.9 mmol/l), in subjects on insulin (7,4% and 8,2 mmol/l), while in subjects on combination therapy, the values were highest (9% and 9.8 mmol/l); the difference in HbA1c was also statistically significant (Kruskal-Wallis test, P = 0.02). An association between HbA1c and glucose values with age, sex, and body mass index has not been established.

Conclusion: A statistically significant difference was observed between HbA1c values and the type of therapy, i.e., the difference was observed between subjects on oral antidiabetics and those on combination therapy, which indicates the importance of additional education of patients on self-control and achieving fasting and postprandial glycemic targets. No statistically significant difference was observed in the parameters of glycemic regulation (fasting glucose, HbA1c) with respect to age, sex and body mass index of the subjects.Key words: type 2 diabetes; glycemia; HbA1c; insulin; oral antidiabetics